Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
